In addition, a higher risk of venous thromboembolism has been reported in patients with c-reactive protein flares early after ICI administration (Moik et al., 2022), and increased secretion of various cytokines associated with inflammatory responses may contribute to coagulation abnormalities. The gene discussed is CRP; the disease is venous thromboembolism.